Y0002020

唑来膦酸 一水合物

European Pharmacopoeia (EP) Reference Standard

• 同義詞: P,P′-[1-羟基-2-（1H-咪唑-1-基）亚乙基]双膦酸 一水合物, [1-羟基-2-（1H-咪唑-1-基）乙烷-1,1-二基]双（膦酸） 一水合物, 唑来膦酸 一水合物
• 經驗公式（希爾表示法）: C₅H₁₀N₂O₇P₂·H₂O
• CAS號碼: 165800-06-6
• 分子量：: 290.10
• MDL號碼: MFCD08448695
• 分類程式碼代碼: 41116107
• NACRES: NA.24

屬性

• 等級: pharmaceutical primary standard
• API 家族: zoledronic acid
• 製造商／商標名: EDQM
• 儲存溫度: 2-8°C
• SMILES 字串: O.OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O
• InChI: 1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2
• InChI 密鑰: FUXFIVRTGHOMSO-UHFFFAOYSA-N

描述

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Zoledronic acid monohydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化／生理作用

唑来膦酸（唑来膦酸盐）是一种双膦酸盐骨吸收抑制剂，是基焦磷酸（FPP）合成酶的抑制剂，其会导致破骨细胞活性的下游抑制并减少骨吸收和转换。它已被用于治疗绝经后的骨质疏松症，佩吉特病、高钙血症，并结合癌症化疗以治疗已经扩散到骨骼的癌症引起的骨损伤。

唑来膦酸（唑来膦酸盐）是一种骨吸收抑制剂，是基焦磷酸合成酶的抑制剂

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

安全資訊

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H315,H319,H335
• 防範說明: P261 - P264 - P280 - P304 + P340 + P312 - P337 + P313
• 危險分類: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• 標靶器官: Respiratory system
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable